Aragen Bioscience Inc, a subsidiary unit of GVK BIO and one of the leading pre-clinical CRO specializing in monoclonal antibody and other large-molecule product development andSerum Institute of India Pvt. Ltd.(Serum), the world's largest vaccine manufacturer, have collaborated for the development of multiple stable cell lines to support Serum’s HIV program.

Serum and Aragen say that they are committed to ‘Accelerating Life Sciences R&D’ with the goal of developing affordable monoclonal antibodies that improve the quality of human life.

Aragenwill leverage its expertise with theirRapTrTMplatformutilizing proprietary vectors and CHO DG44 host cells to develop the cell lines. Combined with the analytics platform, Aragen is set to provide Serum with high expressing celllines enablingSerum to quickly move their program forward into manufacturing. With a proven track record of more than 50 years in developing affordable medicines, Serum will focus its efforts on advancing these novel molecules into impactful vaccines or therapies that treat and prevent diseases world-wide.

“We are delighted to partner with the global leader in Vaccines,” said Manni Kantipudi, Chairman, Aragen, & Chief Executive Officer, GVK BIO. “The Aragen team is recognized globally for its ability to clone and express challenging proteins. Through this collaboration with Serum, we expect to build on this expertise to develop and deliver affordablebiologicals.”

“SIIPL is very pleased to join hands with Aragen.SIIPLisalready in collaboration with IAVI and Scripps Research for discovery of novel monoclonal antibodies against HIV. With our manufacturing capabilities and this collaboration with Aragen to develop stable cell lines, SIIPL will be able to provide cost effective monoclonal antibodies against HIV for the developing and developed world,” statedAdar Poonawalla, CEO, SIIPL.

Aragen is set to provide Serum with high expressing cell lines enabling Serum to quickly move their program forward into manufacturing.